CBIO

Crescent Biopharma, Inc. Common Stock
CBIO

Overview Fund Activity

48 hedge funds and large institutions have $83.1M invested in Crescent Biopharma, Inc. Common Stock in 2022 Q4 according to their latest regulatory filings, with 18 funds opening new positions, 8 increasing their positions, 13 reducing their positions, and 5 closing their positions.

Holders
48
Holders Change
+13
Holders Change %
+37.14%
% of All Funds
0.77%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
18
Increased
8
Reduced
13
Closed
5
Calls
$1.04M
Puts
$5K
Net Calls
+$1.04M
Net Calls Change
+$1.03M

Top Buyers

1
Millennium Management
1
Millennium Management
New York
$2.8M
2
Vanguard Group
2
Vanguard Group
Pennsylvania
$6.9M
3
First Manhattan
3
First Manhattan
New York
$952K
4
Marshall Wace
4
Marshall Wace
United Kingdom
$633K
5
Susquehanna International Group
5
Susquehanna International Group
Pennsylvania
$405K

Top Sellers

1
Renaissance Technologies
1
Renaissance Technologies
New York
$779K
2
NMC
2
NEA Management Company
Maryland
$27.2M
3
BCM
3
Bridgeway Capital Management
Texas
$244K
4
Acadian Asset Management
4
Acadian Asset Management
Massachusetts
$5.89M
5
IP
5
Intellectus Partners
California
$248K
Name Market Value Shares Shares
Change 		Shares
Change %
UBS Group
51
UBS Group
Switzerland
– – -17,262 Closed
JPMorgan Chase & Co
52
JPMorgan Chase & Co
New York
– – -1 Closed
CFGS
53
Concourse Financial Group Securities
Alabama
– – – –
Barclays
54
Barclays
United Kingdom
$0 76 +76 New
1 2
3